Charles Schwab
FDMT icon

Charles Schwab’s 4D Molecular Therapeutics FDMT Stock Holding History

Charles Schwab’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.51M Buy
339,275
+10,896
+3% +$106K ﹤0.01% 2527
2026
Q1 		$3.06M Sell
328,379
-25,012
-7% -$218K ﹤0.01% 2595
2025
Q4 		$2.65M Buy
353,391
+47,534
+16% +$482K ﹤0.01% 2679
2025
Q3 		$2.66M Buy
305,857
+10,816
+4% +$64.6K ﹤0.01% 2683
2025
Q2 		$1.09M Buy
295,041
+12,260
+4% +$43.1K ﹤0.01% 2871
2025
Q1 		$913K Sell
282,781
-25,828
-8% -$122K ﹤0.01% 2871
2024
Q4 		$1.72M Sell
308,609
-29,708
-9% -$233K ﹤0.01% 2727
2024
Q3 		$3.66M Buy
338,317
+452
+0.1% +$7.5K ﹤0.01% 2517
2024
Q2 		$7.09M Buy
337,865
+35,660
+12% +$895K ﹤0.01% 2200
2024
Q1 		$9.63M Buy
302,205
+33,567
+12% +$856K ﹤0.01% 2005
2023
Q4 		$5.44M Buy
268,638
+10,130
+4% +$133K ﹤0.01% 2274
2023
Q3 		$3.29M Sell
258,508
-7,569
-3% -$127K ﹤0.01% 2434
2023
Q2 		$4.81M Buy
266,077
+47,971
+22% +$883K ﹤0.01% 2246
2023
Q1 		$3.75M Buy
218,106
+1,206
+0.6% +$23.5K ﹤0.01% 2328
2022
Q4 		$4.82M Buy
216,900
+5,958
+3% +$92K ﹤0.01% 2229
2022
Q3 		$1.7M Buy
210,942
+34,841
+20% +$316K ﹤0.01% 2626
2022
Q2 		$1.23M Sell
176,101
-13,510
-7% -$131K ﹤0.01% 2718
2022
Q1 		$2.87M Buy
189,611
+5,312
+3% +$83.4K ﹤0.01% 2526
2021
Q4 		$4.04M Buy
184,299
+39,145
+27% +$959K ﹤0.01% 2452
2021
Q3 		$3.92M Buy
145,154
+81,934
+130% +$2.34M ﹤0.01% 2478
2021
Q2 		$1.52M Buy
63,220
+5,253
+9% +$161K ﹤0.01% 2801
2021
Q1 		$2.52M Buy
+57,967
New +$2.57M ﹤0.01% 2600

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Charles Schwab's FDMT Position: Q2 2026 in Review

Charles Schwab increased its 4D Molecular Therapeutics (FDMT) stake by 3.3% in Q2 2026, buying an estimated $106K and bringing the position to 339,275 shares worth $4.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2527.

Charles Schwab first reported a position in FDMT in Q1 2021 and has held it in 22 quarters since. The position peaked at $9.63M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Charles Schwab held 339,275 shares of 4D Molecular Therapeutics worth $4.51M as of Q2 2026.
  • Charles Schwab bought 10,896 4D Molecular Therapeutics shares in Q2 2026, an estimated $106K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2527 holding.
  • Charles Schwab first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Charles Schwab's 4D Molecular Therapeutics position peaked at $9.63M in Q1 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.